How these 4 ASX 200 shares just gained major broker upgrades

Brokers are forecasting substantial 2024 share price gains from these four ASX 200 shares.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Four S&P/ASX 200 Index (ASX: XJO) shares have just gained some sizeable upgrades from leading brokers.

The improved outlook came on the heels of the companies' earnings results.

The brokers forecast these stocks could leap as much as 13% over the coming year. Atop those potential share price gains, two of the companies also just declared all-time high dividends.

So, which ASX 200 shares could charge higher?

I'm glad you asked!

(Broker upgrade figures, courtesy of The Australian.)

A young female investor sits in her home office looking at her ipad and smiling as she sees the QBE share price rising

Image source: Getty Images

These ASX 200 shares could leap higher in 2024

The first ASX 200 share getting an upgrade is Ampol Ltd (ASX: ALD).

The energy stock reported its full calendar year 2023 results on Monday.

Highlights included a 2% year on year increase in earnings before interest and tax (EBIT) – excluding significant items – which came in at $1.30 billion. The company also reported all-time high total sales volumes of 28.4 billion litres in 2023, up 17% from 2022.

And Ampol declared a record high, fully franked final dividend of $1.80 per share.

Macquarie appears impressed with the company's full-year performance and outlook. The broker raised its target price by 11% to $42.50 a share. That represents a potential upside of 13% from current levels.

Cochlear Ltd (ASX: COH) also received a significant upgrade.

The cochlear implant device manufacturer reported its half-year results yesterday.

Highlights included a 20% year on year increase in revenue (in constant currency terms) to $1.11 billion. And underlying net profit was up 21% for the six months to $192 million.

This saw the ASX 200 share declare a record interim dividend of $2 per share, franked at 70%. Management also forecast 10% to 15% growth in the company's cochlear implant units for the full 2024 financial year.

On the back of these result, Wilson raised its price target for Cochlear shares by 15% to $365 a share. This represents an 11% potential upside from current levels.

What other ASX stocks earned broker upgrades?

The third ASX 200 share earning a sizeable broker upgrade is GPT Group (ASX: GPT).

On Monday, the real estate investment trust (REIT) announced its full-year results for 2023.

GPT reported a net loss after tax of $240 million, primarily driven by investment property revaluations of negative $819 million. But funds from operations (FFO) were in line with guidance at $601 million.

And GPT pleased passive income investors with an unfranked 12.5 cent per share final dividend. That brought the full-year payout to 25 cents per share, in line with 2022.

With Aussie interest rates now likely at their peak, GPT forecasts positive leasing growth for its retail and logistic portfolios, while the office segment could continue to struggle.

On the back of these results, JPMorgan raised GPT Group to an overweight rating with a $4.90 price target. That represents a potential 11% upside from current levels.

Which brings us to the fourth ASX 200 share gaining a broker upgrade, Westpac Banking Corp (ASX: WBC).

The big four bank stock released its quarterly results on Monday. And the bank revealed it's holding up well despite inflationary pressures and ongoing competition in the mortgage markets.

Westpac's unaudited net profit (excluding notable items) came in at $1.8 billion, which was in line with the prior corresponding period.

As expected, core net interest margin (NIM) slipped by 0.04% from 2H 2022 to 1.80%.

And with only 31% of the bank's $1.5 billion on market share buyback completed, the Westpac share price could find further support as more shares are taken off the market.

On the back of these results, Barrenjoey raised Westpac shares to an overweight rating with a $26 price target. That represents a potential upside of 1% from current levels.

Westpac also trades on a 5.5%, fully franked trailing dividend yield.

JPMorgan Chase is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear, JPMorgan Chase, and Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Sell buy and hold on a digital screen with a man pointing at the sell square.
Broker Notes

Macquarie shares: Buy, hold or sell?

Two top analysts offer their outlook for Macquarie’s outperforming shares.

Read more »

A steel worker peers out from under his protective headwear which is tipped back on his head as he stares solemnly straight ahead with steel production equipment in the background.
Broker Notes

Bell Potter says this beaten-down ASX materials stock can rise 56%

Down 17% this year, Bell Potter says ASX materials stock has significant upside.

Read more »

A cool young man walking in a laneway holding a takeaway coffee in one hand and his phone in the other reacts with surprise as he reads the latest news on his mobile phone
Broker Notes

This ASX small-cap is tipped to almost double in the next year

Bell Potter just raised its guidance on this ASX small-cap.

Read more »

Man sits smiling at a computer showing graphs.
Broker Notes

6 ASX 200 shares with strengthened buy ratings this week

Brokers have maintained confidence in these ASX 200 stocks amid today's volatile market conditions.

Read more »

A happy person clenching fists in celebration sitting at computer.
Broker Notes

Morgans says hold BHP shares and buy this ASX 200 stock      

Let's see what the broker is saying about these stocks this week.

Read more »

An ASX 200 market analyst holds his hand to his chin and looks closely at his computer screens watching share price movements
Broker Notes

3 ASX 200 shares just upgraded to strong buy — here's what the brokers are saying

Do any of these ASX 200 stocks appeal to you?

Read more »

Person pressing the buy button on a smartphone.
Broker Notes

3 reasons to buy Pro Medicus shares today

A leading analyst believes Pro Medicus shares are now trading at a significant discount.

Read more »

Two men look excited on the trading floor as they hold telephones to their ears and one points upwards.
Broker Notes

Buy, hold, sell: Sigma Healthcare, Macquarie, Santos shares

Brokers reveal their latest ratings and reviews on 3 ASX 200 stocks.

Read more »